To accomplish our goal, we used ICI 182,780 (Faslodex) which is the most potent estrogen receptor antagonist of the class of 7α-alkylamide that has been approved for treatment of postmenopausal breast cancer patients who fail to respond to tamoxifen therapy [23]. Here, ESR1 is linked to breast cancer.